Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.

Luca, F., Oliva, F., Abrignani, M., Di Fusco, S., Gori, M., Giubilato, S., et al. (2024). Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon. JOURNAL OF CLINICAL MEDICINE, 13(5) [10.3390/jcm13051375].

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon

Gori M.;Maloberti A.;
2024

Abstract

Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.
Articolo in rivista - Review Essay
heart failure with preserved ejection fraction (HFpEF); mineralocorticoid receptor antagonists (MRAs); sodium-glucose cotransporter-2 (SGLT2) inhibitors sacubitril/valsartan chronic;
English
28-feb-2024
2024
13
5
1375
none
Luca, F., Oliva, F., Abrignani, M., Di Fusco, S., Gori, M., Giubilato, S., et al. (2024). Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon. JOURNAL OF CLINICAL MEDICINE, 13(5) [10.3390/jcm13051375].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/484239
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
Social impact